TIDMC4XD

RNS Number : 8145J

C4X Discovery Holdings PLC

18 August 2023

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Exercise of Options, Issue of Equity and Total Voting Rights

18 August 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces it has issued 107,500 ordinary shares of 1p each in the Company ("New Ordinary Shares") following the exercise of options by certain employees of the Company.

Admission and Total Voting Rights

Application has been made for the 107,500 New Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 24 August 2023. The New Ordinary Shares will rank pari passu with the existing ordinary shares.

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued share capital now consists of 252,227,097 ordinary shares. Accordingly, the figure of 252,227,097 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 Rupert Dearden (Corporate Broking) 
 
 C4X Discovery Media - Consilium Strategic 
  Communications 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world--leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced candidate molecule design and patient stratification capabilities, generating small molecule drug candidates across multiple disease areas focused on immuno-inflammation. Our commercially attractive portfolio ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have three commercially partnered programmes with one candidate in clinical development.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEDZGMRMRDGFZM

(END) Dow Jones Newswires

August 18, 2023 07:45 ET (11:45 GMT)

C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more C4x Discovery Charts.
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more C4x Discovery Charts.